Lymphoma Clinical Trials in Massachusetts

Showing 41-60 of 240 trials

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+5 more

Carna Biosciences, Inc.120 participantsStarted Aug 2023

Orange, California, United States • Miami Beach, Florida, United States • Tampa, Florida, United States +10 more locations

RECRUITING22 miles

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more

Alliance for Clinical Trials in Oncology2,000 participantsStarted Aug 2022

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +737 more locations

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Lymphoma Trials in Other Cities

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Avo In R/R And Previously Untreated MCL

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Other Conditions in Massachusetts